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DNA methylation changes contribute to bladder carcinogenesis. Trihalomethanes (THM), a class of disinfection by-
products, are associated with increased urothelial bladder cancer (UBC) risk. THM exposure in animal models produces
DNA hypomethylation. We evaluated the relationship of LINE-1 5-methylcytosine levels (LINE-1%5mC) as outcome of long-
term THM exposure among controls and as an effect modiﬁer in the association between THM exposure and UBC risk. We
used a case-control study of UBC conducted in Spain. We obtained personal lifetime residential THM levels and measured
LINE-1%5mC by pyrosequencing in granulocyte DNA from blood samples in 548 incident cases and 559 hospital controls.
Two LINE-1%5mC clusters (above and below 64%) were identiﬁed through unsupervised hierarchical cluster analysis. The
association between THM levels and LINE-1%5mC was evaluated with b regression analyses and logistic regression was
used to estimate odds ratios (OR) adjusting for covariables. LINE-1%5mC change between percentiles 75th and 25th of
THM levels was 1.8% (95% conﬁdence interval (CI): 0.1, 3.4%) among controls. THM levels above vs. below the median
(26 mg/L) were associated with increased UBC risk, OR D 1.86 (95% CI: 1.25, 2.75), overall and among subjects with low
levels of LINE-1%5mC (n D 975), OR D 2.14 (95% CI: 1.39, 3.30), but not associated with UBC risk among subjects’ high
levels of LINE-1%5mC (n D 162), interaction P D 0.03. Results suggest a positive association between LINE-1%5mC and
THM levels among controls, and LINE-1%5mC status may modify the association between UBC risk and THM exposure.
Because reverse causation and chance cannot be ruled out, conﬁrmation studies are warranted.
Introduction
Disinfection by-products (DBP) constitute complex mixtures
of undesired toxic chemicals, including carcinogens formed as
side-products when disinfectants (i.e., chlorine) react with
organic matter. Trihalomethanes (THM), one of the most preva-
lent groups of chlorination DBP, have been used as surrogates of
total DBP in epidemiological studies. Levels of THM in Spain
have been among the highest in Europe.1 Lifetime exposure to
THM in drinking water has been related to urothelial bladder
cancer (UBC) risk,2,3 but the mechanism of action is poorly
understood. UBC is the fourth most prevalent cancer among
Spanish males,4 and is consistently associated with smoking
habits.5
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The carcinogenicity of DBP is attributed to both genotoxic
and non-genotoxic mechanisms. The proposed genotoxic mecha-
nism requires intracellular conjugation of the brominated com-
pounds through glutathione S-transferase theta 1, GSTT1.6-10
Given that this mechanism does not explain completely the carci-
nogenic effect observed in animals or humans, non-genotoxic
mechanisms remain a plausible explanation. Experiments in
rodents show that exposure to THM and haloacetic acids induces
alterations in global and specific genes DNA methylation,
increases mRNA expression of protooncogenes c-myc and c-jun,
and induces kidney and liver tumors.11-14 Although experimental
evidence suggests the plausibility of this mechanism of action,
the relationship between chronic THM exposure and epigenetic
changes has not been explored in human populations.
Long Interspersed Element-1 (LINE-1) is a retrotransposon
highly repeated in the genome, and its CpG site methylation can be
used as a surrogate measure of global DNA methylation.15 LINE-1
is composed of highly repeated sequences, each 6,000 to 8,000 base
pairs in length.16,17 The human genome contains more than
500,000 copies of LINE-1, of which 3000 are potentially transpos-
able.18 LINE-1 retrotransposition has been related to several diseases
including various types of cancer.19,20DNAmethylation is the main
mechanism that inhibits retrotransposon expression preventing
genomic damage.20,21 Several studies have used LINE-1methylation
as a biomarker of susceptibility to cancer.22 Both low and high levels
of 5-methylcytosine (5mC) within LINE-1 sequences in leukocytes
have been linked to an increased risk of UBC.23-26We evaluated the
relationship of LINE-1 5-methylcytosine levels (LINE-1%5mC) as
outcome of long-term THM exposure and as an effect modifier in
the association between long-term THM exposure andUBC risk.
Results
Overall, 2,090 study subjects provided a blood sample for
DNA extraction (1,083 cases and 1,007 controls).27 Of these,
1,849 [88.5%; 957/1,083 (88.4%) cases and 892/1,007 (88.6%)
controls] had available samples for LINE-1%5mC measurements.
A total of 1,107 (53.0%) subjects had reliable or high quality
interview data, as reported by the interviewer, and more than 70%
of y in the exposure window (see methods below) with valid
THM data, representing 548 (50.6%) cases and 559 (55.5%) con-
trols in the final analysis. We compared sex, age, area and smoking
status between subjects included and excluded from the analysis.
Statistically significant differences were found for age (excluded
subjects were, on average, 2.7 y older than those included, P < 0
.001) and area (fewer subjects excluded from Alicante, and more
subjects excluded from Manresa and Barcelona). No differences
were found for case-control status, sex ratio, and smoking status.
Median age of study participants was 66 y (range D 20–80 y)
and 88.1% were men. Smoking status showed statistically signifi-
cant differences between cases and controls (Table 1), which
were maintained in logistic regression models adjusted for age,
sex, and area (data not shown). Average LINE-1%5mC level
showed a bimodal distribution, overall, by case-control status
(Supplemental Material, Figure S1, panels A and B), and within
Table 1. Distribution of cases and controls with LINE-1% 5-methylcytosine (LINE-1%5mC) and trihalomethane (THM) data in the Spanish Bladder
Cancer/EPICURO (SBC/EPICURO) study
Variable Cases n D 548 n(%) Controls n D 559 n(%) P1
Sex
Male 477 (87.0) 498 (89.1) 0.3
Female 71 (13.0) 61 (10.9)
Age (y)
Mean § SE 64.5 § 0.4 63.3 § 0.4 0.07
Area of residence
Alicante 47 (8.6) 60 (10.7) 0.6
Asturias 238 (43.4) 241 (43.1)
Barcelona 86 (15.7) 97 (17.4)
Manresa 24 (4.4) 17 (3.0)
Sabadell 51 (9.3) 49 (8.8)
Tenerife 102 (18.6) 95 (17.0)
Smoking
Never smokers 101 (18.4) 195 (34.9) <0 .001
Moderate smokers 55 (10.0) 89 (15.9)
Heavy smokers 392 (71.5) 275 (49.2)
Average residential THM levels (mg/L)
Mean § SE 33.2 § 1.2 34.2 § 1.2 0.6
"26 mg/L 251 (45.8) 272 (48.7) 0.3
>26 mg/L 297 (54.2) 287 (51.3)
LINE-1%5mC
Mean § SE 59.6 § 2.1 58.8 § 2.1 0.8
<64 % 456 (83.2) 489 (87.5) 0.05
#64 % 92 (16.8) 70 (12.5)
1
x
2 test for proportions, t-test for continuous variables comparing cases vs. controls.
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the different study areas, both sexes, all the hospitals, and over the
4 y of recruitment (data not shown). By CpG, the 1st and 3rd
sites showed higher methylation levels than the 2nd and 4th sites
(Supplemental Material, Figure S1, panels C and D). The den-
drogram from the unsupervised hierarchical cluster showed 2
clusters. The k-means cluster analysis selected a cut-off at 64%
between clusters. LINE-1%5mC was classified as low-intermedi-
ate (<64%) and high ( 64% methylation). We visually
inspected the scatterplots of the first vs. the second components
from a principal component analysis of the 4 CpGs, according to
different variables to observe potential batch effects (technical
and not attributable to covariables). A suggestion of a batch effect
was found by the y of interview, which corresponds to time of
inclusion and blood collection and was not related to case/control
status (Supplemental Material, Figure S2).
LINE-1%5mC levels dichotomized at 64% showed statisti-
cally significant differences between cases and controls (Table 1),
which remained in logistic regression models adjusted for age,
sex, and area (data not shown). Average LINE-1%5mC levels as
a continuous variable were slightly different between cases and
controls but multivariable analysis showed no statistically signifi-
cant differences (Table 2). LINE-1%5mC levels were lower
among females (both among cases and controls), and were not
significantly associated with age and smoking status (Table 2). A
statistically significant interaction was found for case-control
status and age (interaction P D 0.03). This interaction disap-
peared after including THM in the models and was not further
explored. Methylation levels by area were similar, and adjustment
for area instead of hospital as a cluster showed similar results (not
shown in tables). Change between the percentiles 25th and 75th
of average residential THM levels were associated with increased
LINE-1%5mC levels among controls (bD 1.8%) and a negative,
not significant association was observed among cases (b D
-2.1%) (interaction P D 0.02) (Table 2). The negative associa-
tion among cases was driven by a small group with highest
LINE-1%5mC levels ( 64%, n D 162) (results not shown). The
association with THM levels categorized by the median showed
similar trends but there were no statistically significant differences
for controls (b D 1.2%), while the association among cases was
statistically significant (b D ¡6.6%) (Table 2). The association
between THM levels and LINE-1%5mC is shown graphically in
Figure 1. Methylation levels were similar among controls (59%),
non-muscle invasive cases (59%) and invasive cases (60%), het-
erogeneity P D 0.3. No differences were observed between mus-
cle invasive (>T2, n D 111) and non-invasive (Ta, and T1
tumors, n D 437) bladder cancer risk vs. controls.
Odds ratios of UBC were 2.03 (95% CI: 1.27, 3.82) among
moderate smokers and 4.48 (95% CI: 3.11, 6.44) among heavy
smokers, compared to never smokers, P-trend<0.001 (results
not shown in tables). Average lifetime THM levels were
Table 2. Levels of LINE-1% 5-methylcytosine (LINE-1%5mC) in cases and controls, and b coefﬁcient from b regression of LINE-1%5mC, according to
individual characteristics in the Spanish Bladder Cancer/EPICURO (SBC/EPICURO) study
Variable
LINE-1%5mC
Mean § SE
LINE-1%5mC change1
(95% CI)
Cases Controls Cases Controls All
59.6 § 2.1 58.8 § 2.1
Case-control status
Control Reference
Case 0.4 (¡2.9, 3.6)
Age (y)
Mean (64 yrs) centered 0.2 (¡0.01, 0.3) ¡0.1 (¡0.2, 0.1) 0.04 (¡0.1, 0.1)
interaction P 0.03
Sex
Male 59.6 § 2.2 59.0 § 2.2 Reference Reference Reference
Female 59.4 § 5.8 57.6 § 6.3 ¡2.2 (¡8.7, 4.2) ¡7.2 (¡12.7, ¡1.7) ¡4.5 (¡9.6, 0.5)
interaction P 0.14
Smoking
Never 59.6 § 4.9 58.5 § 3.5 Reference Reference Reference
Moderate 59.7 § 6.6 59.1 § 5.2 ¡3.4 (¡11.3, 4.5) 3.1 (¡0.2, 6.5) 1.1 (¡2.7, 4.8)
Heavy 59.6 § 4.9 58.5 § 3.5 ¡1.6 (¡7.7, 4.4) 2.1 (¡3.0, 7.1) 0.9 (¡3.4, 5.2)
interaction P 0.30
Average residential THM levels (mg/L)
All (nD 1107)
As continuous Change between 25th (10 mg/L) and 75th
(50 mg/L) percentile2
¡2.1 (¡4.4, 0.2) 1.8 (0.1, 3.4) ¡0.03 (¡1.2, 1.2)
interaction P 0.02
In categories
$26 mg/L 59.9 § 2.5 59.0 § 2.5 Reference Reference Reference
>26 mg/L 59.1 § 2.2 58.8 § 2.3 ¡6.6 (¡11.5, ¡1.7) 1.2 (¡3.1, 5.5) ¡2.6 (¡5.9, 0.7)
interaction P 0.02
1Beta coefﬁcient (in percentages) from robust b regression adjusted for sex, age, y of blood drawing and hospital (as cluster). The All column is additionally
adjusted for case-control status.
2Based on the ﬁtted curve between LINE-1%5mC and squared root THMs.
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associated with an increased UBC risk in the overall population,
with an OR of 1.86 (95% CI: 1.25–2.75) when comparing sub-
jects exposed to THM levels above vs. below the population
median (26 mg/L), P-trend D 0.002 (Table 3). The OR of blad-
der cancer for P75th compared to the P25th of THM levels was
1.29 (95% CI: 1.004, 1.65). Among the interactions tested
(THM*LINE-1%5mC low-intermediate/high methylated sub-
jects, smoking*THM, and smoking*LINE-1%5mC low-inter-
mediate/high methylated subjects), only the THM*LINE-
1%5mC was statistically significant (interaction P D 0.03). In
the less methylated group (<64% LINE-1%5-mC), OR of UBC
increased with THM levels whereas THM levels were not associ-
ated with risk of UBC in the most methylated subpopulation
(!64% LINE-1%5mC) (Table 3). Alternative analyses using
generalized additive models and conditional logistic regression
models did not provide a better model fit.
Discussion
Our results show a slight positive association between THM
exposure and LINE-1%5mC levels among controls. A non-statis-
tically significant negative trend was found among cases, driven
by a small group with highest LINE-1%5mC levels (!64%,
n D 162). The LINE-1 methylation status modified the associa-
tion between THM levels and UBC risk. The OR of UBC
increased with THM levels in the low-intermediate methylated
subjects (<64%), whereas the association between THM expo-
sure and UBC risk was not observed among those with the high-
est LINE-1%5mC levels (!64%).
DBPs, and specifically some THM and haloacetic acids, had
been related to a decrease in DNA methylation levels in mice.
Our results differ from the experimental evidence showing lower
methylation levels among rats exposed to THM.11 In our data,
THM exposure did not show an association with LINE-1%5mC
for all the subjects. The difference with experimental evidence
may be partly explained by interspecies differences and non-com-
parable exposures. In rodent experiments, THMs were
administered at high doses and usually per gavage and methyla-
tion sites selected were specific oncogenes.11 On the contrary, in
human populations the drinking water exposure is chronic, at
very low doses, and through multiple pathways (ingestion, inha-
lation, skin absorption) resulting in different pharmacokinetics,
and may be altered due to water handling (filtering, fluid mix-
tures, boiling, cooling, and freezing).28 Our results are plausible
given that one of the mechanisms proposed for THM carcinoge-
nicity is related to cytotoxicity and cell regeneration.29 This
mechanism may affect DNA methylation landmarks because of
rapid cell proliferation generating hypermethylated and hypome-
thylated adapted cell clones,30 the former being clusters of cells
more resilient to environmental toxicants, as seen in controls,
and the latter being more susceptible to DNA dysregulation and/
or to enter into apoptosis, as seen in cases. However, the observed
change of magnitude in LINE-1%5mC levels cannot conclu-
sively associate this observation to THM exposure and/or either
could not be biologically relevant in terms of LINE-1 activation.
Table 3. Odds ratio (OR) and 95% conﬁdence interval (CI) of bladder cancer associated with trihalomethane levels and effect modiﬁcation by LINE-1%
5-methylcytosine levels (LINE-1%5mC) status in the Spanish Bladder Cancer/EPICURO (SBC/EPICURO) study
LINE-1%5mC <64 % (n D 945) LINE-1%5mC !64 % (n D 162) All (n D 1107)
Average residential THM level (mg/L)
Cases/
Controls OR1 (95% CI)
Cases/
Controls OR1 (95% CI)
Cases/
Controls OR1 (95% CI)
As continuos
Change between 25th (10 mg/L) and 75th
(50 mg/L) percentile2
456/489 1.47 (1.12, 1.94)** 92/70 0.62 (0.32, 1.20) 548/559 1.29 (1.00, 1.65)*
interaction P (continuous) 0.03
In categories
"26 mg/L 198/239 Reference 53/33 Reference 251/272 Reference
>26 mg/L 258/250 2.14 (1.39, 3.30)*** 39/37 0.80 (0.28, 2.26) 297/287 1.86 (1.25, 2.75)**
interaction P (categories) 0.08
P compared with controls in the reference *"0 .05, **"0 .01, and ***"0 .001.
1OR adjusted for sex, age, area of residence, smoking (never smokers, moderate smokers, heavy smokers).
2Based on the ﬁtted curve between LINE-1%5mC and squared root THMs.
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Figure 1. Marginal predictive values of LINE-1%5mC in cases and con-
trols at different lifetime exposures to trihalometanes with 95% conﬁ-
dence intervals.
www.landesbioscience.com 1535Epigenetics
D
o
w
n
lo
ad
ed
 b
y
 [
Im
p
er
ia
l 
C
o
ll
eg
e 
L
o
n
d
o
n
 L
ib
ra
ry
] 
at
 0
3
:2
7
 3
0
 J
an
u
ar
y
 2
0
1
5
 
Changes in LINE-1%5mC levels have been associated with an
increased bladder cancer risk in several observational studies in
humans. In a larger subset of the current study, a U-shape rela-
tionship was observed between LINE-1 and bladder cancer
risk.25 In a bladder cancer case control study conducted in China,
non-smokers with LINE-1%5mC levels in the lowest tertile
(<81.2%) had an odds ratio of bladder cancer of 1.91 compared
to those in the highest tertile ( 82.52%).23 Similarly, in the
New Hampshire US bladder cancer study only subjects in the
lowest decile of LINE-1%5mC (<74%) compared to the highest
decile (>84%) had an odds ratio of bladder cancer of 1.80. This
relationship was confounded by gender (lower levels in females),
cumulative arsenic exposure and non-invasive cancer versus inva-
sive cancer, but no interaction was found for smoking.24 In a
pooled nested case/control studies of US and Finland26 an odds
ratio of bladder cancer of 1.82 in male smokers was found com-
paring the lowest quartile (!82.9% in US and !78.1% in Finish
study) to the quartiles 2 to 4. These results are comparable to our
findings, although our population levels are lower than those
reported in these studies. LINE-1%5mC levels reported can be
summarized as Chinese > US > Finnish-Northern European >
Spain-Southern European populations, and differences can be
attributed to ethnic differences and specific lifestyle variables
such as diet.23 Our data corroborated that LINE-1%5mC levels
were lower in females, but, as in all the previous studies, age and
smoking were not consistently related to methylation levels.
However, we did not find differences in LINE-1%5mC levels
between invasive and non-invasive bladder cancer subjects as
observed in other studies.24 Finally, the less methylated subgroup
showed an association between UBC risk and THMs. This is
consistent with previous reports in which less methylated sub-
jects, either at LINE-1 or global DNA methylation, were at
higher risk of UBC.23,24,30
In our study, methylation status was assessed using LINE-
1%5mC levels in granulocyte DNA while other studies used lym-
phocyte, buffy coat and whole blood cells DNA. In our data,
granulocyte and lymphocyte LINE-1%5mC levels were highly
correlated.31 Nonetheless, the mean LINE-1%5mC observed
(59.2%) was lower compared to previous reports in other ethnic
groups and DNA cell sources.23,24,26 However, even if a propor-
tion of the differences among studies may be attributed to differ-
ent cell epigenetic landmarks or the ethnic origin of subjects, we
cannot disregard other unmeasured technical aspects such as dif-
ferent performance of the sequencing primers in our popula-
tion.15 It is important to acknowledge that LINE-1, and among
them L1Hs, only provide a limited view of the methylation status
and do not measure whole DNA methylation, which may be dif-
ferently altered under the same exposure conditions.
The sample size, the laboratory techniques, and the statis-
tical analyses constitute important strengths in our study.
Data were derived from a large hospital based case-control
study with a rigorous exposure assessment of THM and
information of potential confounders. High quality gold-stan-
dard quantifiable laboratory techniques, pyrosequencing, were
used to estimate methylation levels in granulocyte DNA
LINE-1%5mC. Robust statistical strategies including b
regression for proportions and cluster analysis were used to
reduce bias in the analyses. The b regression deals with out-
comes bounded between 0 and 1, which may present hetero-
skedasticity and asymmetries in the distribution.32
Methylation status of a CpG is dichotomous (methylated vs.
unmethylated), but it is quantified in the laboratory as a pro-
portion (% methylated CpGs) making this regression suitable
for analyzing LINE-1%5mC levels as the outcome. When
LINE-1%5mC was used as a confounder, the variable was
categorized to avoid non-linear trends of the distribution or
complicated transformations, which obscure the interpretation
of the data. In literature, methylation is either categorized
using arbitrary cut-offs such as <20%, 20–80%, and
>80%,33,34 or using population specific cut-off based on per-
centiles of controls.23,24,26 In our study, only few subjects
(n D 9) were above 80%. Instead of selecting a percentile,
the selected approach was using a data-driven unsupervised
cluster approach. This strategy separated naturally clustered
subpopulations for the analysis, reducing the chance to bias
the analysis because of an arbitrary selected cut-off.
A limitation of this study is the inability to establish temporal-
ity of the outcomes evaluated in relation with UBC development.
When evaluating LINE-1%5mC as an outcome of THM expo-
sure, we assume that methylation levels are the consequence of
cumulative lifetime exposure to THM. However, given that we
only have one spot sample, we cannot exclude reverse causality
(methylation levels due to cancer or other disease, instead of
being a consequence of THM exposure). This limitation is inher-
ent to the case-control design in long latency diseases such as can-
cer. Nevertheless, as no differences were found between different
cancer stages and most of the study cases were at non-invasive
stages; changes in methylation levels due to a cancer systemic
response are very unlikely. Given that most of the historical expo-
sure data is based on questionnaires, we cannot exclude recall
bias, expected to be non-differential. A categorical variable that
assessed the reliability of the data provided though the question-
naire, as evaluated by the interviewer, was included. Those sub-
jects with unreliable interviews were excluded from analyses. In
addition, only those subjects with more than 70% of yearly his-
torical THM estimates in the exposure time window were ana-
lyzed to reduce misclassification. However, measurement error in
THM level estimates may still be present.
Other limitations are technical due to the laboratory meth-
ods used or potential batch effects. Pyrosequencing had some
important limitations: first, as we used predesigned primers
and the measured point is methylated vs unmethylated, we
cannot rule out polymorphisms in the DNA strands (i.e.,
presence of SNP sites) that may affect performance of the
technique.35 Second, pyrosequencing detection limit per CpG
site is 5%, thus measured lower differences may be unreli-
able.36 In addition, the most methylated and the least meth-
ylated extremes are not easily detected and even 100%
methylated blanks may only produce signals around »80%
methylation.26 On the other hand, we observed variation that
was not explained by any covariable tested. Year of interview
(blood collection) and hospital were used as proxies of
1536 Volume 9 Issue 11Epigenetics
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technical variability (time of storage and/or differences in
blood sample handling). These factors may affect biomarker
performance due to DNA degradation by sample handling,
specially freezing delays and blood conservation. The proto-
cols, storage conditions and sample management were not
changed during the collection, so this only can be explained
due to unmeasured individual sample conditions, presence of
SNPs or actual LINE-1%5mC levels differences because of
other unmeasured confounders. We included the proxies as
confounders in adjusted models when modeling LINE-
1%5mC.37 However, if this was actually a batch effect, we
cannot assess the extent to which it may alter our results.
In summary, results suggest a positive association between
LINE-1%5mC and THM levels among controls, and LINE-
1%5mC status may modify the association between UBC risk
and THM exposure. Because samples were collected post-diagno-
sis and the small group in the highest methylation levels, reverse
causality and chance cannot be ruled out and future studies are
warranted to confirm these results.
Materials and Methods
Study design and participants
Data were obtained from participants in the Spanish Bladder
Cancer (SBC)/EPICURO study, a multicenter, hospital-based,
case-control study conducted from June 1998 to December 2001
in Spain. Subjects were recruited at 18 hospitals in Alicante,
Asturias, Barcelona, Manresa, Sabadell and Tenerife. Cases were
patients aged 20–80 y living in the geographic catchment areas of
the participating hospitals, with histologically confirmed primary
bladder cancer based on the 1999 system of the WHO and the
International Society of Urological Pathology.38 Controls were
inpatients of the participating hospitals selected to have diagnoses
unrelated with the main UBC risk factor (smoking). Controls
were individually matched to cases by sex, age (§5 y), and geo-
graphic area of residence. The study was approved by the Institu-
tional Review Boards of the participating centers and participants
provided informed consent before participation. A total of 1457
eligible cases and 1465 eligible controls were identified. Partici-
pation rates were 84% for cases (n D 1219) and 87% for controls
(n D 1271).
Personal interview
Trained interviewers administered a comprehensive com-
puter-assisted personal questionnaire to participants during their
hospitalization. Collected data included socio-demographic char-
acteristics, smoking habits, family history of cancer, medical,
occupational, and residential histories from birth to the time of
interview (all residences of at least 1 y), average daily consump-
tion of water and water-based fluids (e.g., coffee and tea), and
average frequency and duration of showering and bathing. For all
dwellings, the y lived in a residence, full address, city, province,
region, and country were requested. Zip codes in Barcelona were
obtained through the address to estimate the water purveyors’
areas.
THM exposure assessment
Exposure assessment has been described elsewhere.39,40 In
brief, historical water source, treatment and quality data were
requested from water companies and local authorities. In the
absence of historical THM measurements, water source and cur-
rent levels were used to estimate the levels in the past. Annual
THM levels were modeled back to 1920 assuming unchanged
level for a constant water source. Levels changed proportionally
to surface water percentage if water source changed. A zero
THM level was assumed for those y before chlorination started.
Residential THM levels per subject were calculated by merging
individual and municipal databases by y and municipality of resi-
dence. A time-weighted average level in all residences since 15 y
old to the time of interview was calculated for all subjects as pre-
viously described.39 We refer to this time period as the study
‘exposure window’.
Quantification of LINE-1%5mC levels in granulocytes
A blood sample or a saliva sample was requested from all
the subjects in the main case-control study for genetic analy-
ses.27 Buffy coat, whole blood and purified lymphocytes have
been used in previous studies. For this study, the granulocyte
fraction was used and results were compared against purified
lymphocytes.31 Granulocyte DNA was extracted using stan-
dard methods. DNA was treated with bisulfite using EZ-96
DNA METHYLATION-GOLDTM KIT (Zymo Research,
Irvine, CA, USA) to transform unmethylated cytosines into
uracil, leaving the methylated cytosine unchanged. Polymerase
chain reaction amplified the bisulfite-treated DNA sequence
using a group of modified 3 DNA primers, as previously
described.41 This approach measures%5mC levels of the 4
CpG sites located immediately after the sequencing primer at
LINE-1 promoter region, between nucleotides 318–331,
within the human LINE-1 transposon (L1Hs) DNA 5’ UTR,
GenBank accession number X58075.31,42 Methylation levels
were quantified by pyrosequencing using the PyroMarkTM
Q24 System (QIAGEN, Valencia, CA, USA). The subject
LINE-1%5mC is the percentage of methylated cytosines over
the sum of methylated and unmethylated cytosines. Levels of
methylation of the 4 CpG sites were averaged to a single
LINE-1%5mC level. A total of 302 randomly selected sam-
ples (174 cases and 128 controls) were run in duplicate. The
intra-assay coefficient of variation was 4.53%, technical causes
of variation has been discussed elsewhere.31 The intraclass
correlation coefficient (ICC) of LINE-1 duplicates among
samples with less than 5% coefficient of variation (n D 216,
72% of duplicates) and adjusting by technical duplicates
(using a 2 way random effects ANOVA test) was 0.25 (95%
CI: 0.12, 0.37) within subjects and 0.40 (95% CI: 0.22,
0.54) between subjects. We used the mean of the duplicates
in the analysis. As we were unable to assess the full set of
measurements by duplicate, we imputed the coefficient of
variation for all the subjects included in the analyses. We
compared a model including this variable and without it and
estimates were consistent. We thus decided to pool all the
available samples for the analyses.
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Statistical methods
Bivariate analyses included x2 to compare proportions, t-test
to compare mean differences, and proportion test to compare
proportion differences. Analyses of average methylation levels
(%) of several CpG sites in the LINE-1 repetitive sequences usu-
ally show a high peaked distribution which obscures underlying
modes due to differential methylation between CpG sites.33 To
observe differentially methylated subpopulations, LINE-1%5mC
distribution was classified using an unsupervised hierarchical
cluster dendrogram to observe potential clustering and a k-means
cluster approach was used to select a cut-off. Principal compo-
nent analysis using the 4 CpGs was used to test potential batch
effects (defined as technical sources of variation that have been
added to the samples during handling) related to blood sample
manipulation (i.e., y of blood drawing or hospital).
We used b regression to estimate differences in levels of
LINE-1%5mC by different covariates in multivariable analyses,
to deal with a variable bounded between 0 and 1.32 The relation-
ship between THM and LINE-1 levels was assessed separately for
cases and controls, and for all combined by including an interac-
tion term in the model. Beta coefficients were multiplied by 100
to interpret results as percentages. Models were adjusted by sex,
age, y of blood drawing and hospital as cluster. Standard errors
were robust adjusted (Huber-White Sandwich method). To
obtain a linear relationship between average lifetime residential
THM levels and LINE-1%5mC, THM concentration (mg/L)
was square root transformed. Based on this model, we derived
the change in LINE-1%5mC between percentiles P25th to
P75th, in order to interpret results in the original (untrans-
formed) scale. We used generalized additive models to observe
graphically the dose-response relationship between THM
levels and LINE-1%5mC and identify eventual non-linear
associations.
We applied logistic regression to assess the UBC risk associ-
ated with THM exposure adjusted for age, sex, geographic area
of residence and smoking. Smoking was classified in three
groups: never smokers, moderate smokers (i.e., former or current
smokers of less than 20 pack-y), and heavy smokers (i.e., more or
equal to 20 pack-y). Stratified analyses and interaction terms
were used to test the modification of the UBC risk associated
with THM exposure by LINE-1%5mC status. Different ordered
and multinomial logistic regression approaches were considered
for sensitivity analyses. Stereotype logistic regression, a class of
ordered logistic regression,43 was used to evaluate risk of non-
muscle-invasive and muscle-invasive bladder cancer risk vs. con-
trols for different covariates. In order to interpret results in the
original (untransformed) scale, we derived the change in UBC
risk between percentiles 25th to 75th of THMs in the model
using the square root of THMs.
Interaction was evaluated by introducing the product of the
variables. Likelihood ratio tests comparing models with and with-
out multiplicative interaction terms were used to calculate the
interaction P. In robust models, the Wald test was used to
approximate the interaction P. Marginal effects were calculated
using the predicted probabilities of the events at different cut-offs
for continuous or categorical by continuous interactions holding
constant the other equation variables.44,45
To rule out bias due to averaging the 4 tested CpGs, 3 differ-
ent variables were used in alternative analyses instead of average
LINE-1%5mC: 1) the first CpG; 2) the first and second compo-
nent from a principal component analysis of the 4 CpG sites;
and 3) a mixed effects model using the 4 CpG as the outcome,
using the nucleotide order as a random effect (data not shown).
Results were considered statistically significant if the nominal P
was <0.05. All tests were 2-tailed. Statistical analyses were per-
formed using Stata Statistical Software; release 12.1 (StataCorp
LP, College Station, TX), and the Betafit module.46 Results were
similar between models so we used the average of CpGs and a b
model for our analyses.
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